Lupus & antiphospholipid syndrome
Disease activity and quality of life in patients with systemic lupus erythematosus: a validation study using the SLE disease activity score (SLE-DAS)
Authors' conclusion
SLE-DAS remission was associated with better QoL in patients with SLE. Reduction in SLE-DAS over time correlates significantly with improvement in health-related QoL.
Study context
- Population
- Consecutive patients fulfilling the ACR/SLICC criteria for systemic lupus erythematosus (SLE) (92.9% women; age 48.6 ±13.3 years)
- Participants
- 510 patients
- Comparison
- SLE-DAS index-based remission vs no remission
- SLE-DAS index-based remissionn = 337
- Outcome
- Relationship between disease activity (SLE-DAS) and quality of life (QoL) (LupusPRO)
Methodological detailsconsecutive patients, 6-month re-evaluation of patients with active SLE
- Consecutive patients
- 6-month re-evaluation of patients with active SLE
Performance
As reported in the abstract
LupusPRO HRQoL score · baseline
SLE-DAS index-based remission
76.8
± 16.2
No remission
69.0
± 16.8
P < 0.01
Further findings
SLE-DAS disease activity categories at baseline
- Remission (score ≤2.08)
- 364(71.3%)
- Mild (2.08-7.64)
- 75(14.7%)
- Moderate/high (>7.64)
- 71(13.9%)
Correlation of SLE-DAS with SLEDAI-2K and Physician Global Assessment (PGA) · baseline
- Rho with SLEDAI-2K
- 0.92
- Rho with PGA
- 0.62
- p<0.01 in both
Patients with PGA ≥0.5 at baseline reassessed (n=139) · month 6
- Improvement in SLE-DAS
- 77(55.4%)
- Achieved SLE-DAS index-based remission
- 61(43.9%)
Change in SLE-DAS vs change in LupusPRO HRQoL score · month 6
- Rho
- −0.30
- p<0.01
Original publication
Disease activity and quality of life in patients with systemic lupus erythematosus: a validation study using the SLE-DAS. Clin Exp Rheumatol. Published 26 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →